{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:29Z","timestamp":1792525229084,"version":"4.5.0"},"reference-count":80,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>Major discoveries in the past have laid the foundation on which modern diabetes research has been built, and future findings can be anticipated. From this groundwork, we have pursued studies evaluating the role of \u03b2-cell function and \u03b2-cell mass in the pathogenesis of type 2 diabetes. In considering \u03b2-cell function, studies of \u03b2-cell responses to intravenous and oral glucose have highlighted the critical nature of interpreting these responses in the face of the prevailing insulin sensitivity, and not as isolated responses. The critical role of \u03b2-cell dysfunction in the pathogenesis of prediabetes and diabetes has become apparent. When prediabetes is present, \u03b2-cell function is reduced by 40%, while in recent-onset type 2 diabetes it is reduced by &amp;gt;80%. In youth with prediabetes and type 2 diabetes, \u03b2-cell function deteriorates at a faster rate than in adults, compatible with their disease being more aggressive. From clinical trials in both age groups, the progression of \u03b2-cell dysfunction over time is the basis for deteriorating glycemia, with none of the currently available glucose-lowering agents able to halt this inexorable decline. Reflecting on \u03b2-cell mass, this is clearly reduced in people with type 2 diabetes. One basis for this is islet amyloid, which is formed from the normal \u03b2-cell secretory peptide islet amyloid polypeptide (IAPP) (or amylin). The process of amyloid formation promotes oxidative stress, inflammation, and \u03b2-cell death, creating a destructive feed-forward that exacerbates disease progression. Experimental studies demonstrate that reducing amyloid formation reduces oxidative stress, inflammation, and the loss of \u03b2-cell mass. Ultimately, preserving \u03b2-cell function and mass is critical in striving to prevent and treat type 2 diabetes. Future tactics have to deviate from the current approaches if we are going to be successful in reducing the deleterious effects of a dysfunctional \u03b2-cell in type 2 diabetes.<\/jats:p>","DOI":"10.2337\/dbi25-0024","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:01:44Z","timestamp":1792522904000},"page":"1954-1967","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting the \u03b2-Cell: The Key to the Type 2 Diabetes Puzzle: The 2025 Banting Medal for Scientific Achievement Award Lecture"],"prefix":"10.2337","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-9002","authenticated-orcid":false,"given":"Steven E.","family":"Kahn","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington , Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"2026102015013949200_B1","volume-title":"S.J. Res. 257: Joint Resolution: To Designate the Month of November 1982, as \u201cNational Diabetes Month.","author":"United States Senate and House of Representatives","year":"1982"},{"key":"2026102015013949200_B2","volume-title":"S. Res. 899: A Resolution Designating November 2024 as \u201cAmerican Diabetes Month.","author":"United States Senate (","year":"2024"},{"key":"2026102015013949200_B3","volume-title":"The Discovery of Insulin.","author":"Bliss","year":"1982"},{"key":"2026102015013949200_B4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1084\/jem.5.5.527","article-title":"The relation oe diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands oe Langerhans","volume":"5","author":"Opie","year":"1901","journal-title":"J Exp Med"},{"key":"2026102015013949200_B5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2337\/diab.4.5.367","article-title":"Quantitative estimation of the pancreatic islet tissue in diabetic subjects","volume":"4","author":"Maclean","year":"1955","journal-title":"Diabetes"},{"key":"2026102015013949200_B6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1172\/JCI104130","article-title":"Immunoassay of endogenous plasma insulin in man","volume":"39","author":"Yalow","year":"1960","journal-title":"J Clin Invest"},{"key":"2026102015013949200_B7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diab.9.4.254","article-title":"Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immuno-assay technic","volume":"9","author":"Yalow","year":"1960","journal-title":"Diabetes"},{"key":"2026102015013949200_B8","unstructured":"Banting\n              FG\n            \n          . Nobel Prize lecture: diabetes and insulin, 1925. Accessed 25 May 2025. Available from https:\/\/www.nobelprize.org\/prizes\/medicine\/1923\/banting\/lecture\/"},{"key":"2026102015013949200_B9","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diab.42.11.1663","article-title":"Quantification of the relationship between insulin sensitivity and \u03b2-cell function in human subjects: evidence for a hyperbolic function","volume":"42","author":"Kahn","year":"1993","journal-title":"Diabetes"},{"key":"2026102015013949200_B10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI7231","article-title":"The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus","volume":"104","author":"Weyer","year":"1999","journal-title":"J Clin Invest"},{"key":"2026102015013949200_B11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2337\/dc08-1478","article-title":"Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels","volume":"32","author":"Utzschneider","year":"2009","journal-title":"Diabetes Care"},{"key":"2026102015013949200_B12","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s00125-020-05245-x","article-title":"Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia","volume":"63","author":"Esser","year":"2020","journal-title":"Diabetologia"},{"key":"2026102015013949200_B13","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0168-8227(98)00038-2","article-title":"Assessing the potential for alpha-glucosidase inhibitors in prediabetic states","volume":"40","author":"Holman","year":"1998","journal-title":"Diabetes Res Clin Pract"},{"key":"2026102015013949200_B14","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2026102015013949200_B15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on \u03b2-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"2026102015013949200_B16","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJMoa2200433","article-title":"Glycemia reduction in type 2 diabetes - glycemic outcomes","volume":"387","author":"GRADE Study Research Group","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102015013949200_B17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/dc23-1070","article-title":"Longitudinal effects of glucose-lowering medications on \u03b2-cell responses and insulin sensitivity in type 2 diabetes: the GRADE randomized clinical trial","volume":"47","author":"Rasouli","year":"2024","journal-title":"Diabetes Care"},{"key":"2026102015013949200_B18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2026102015013949200_B19","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.2337\/diabetes.54.8.2404","article-title":"Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program : effects of lifestyle intervention and metformin","volume":"54","author":"The Diabetes Prevention Program Research Group","year":"2005","journal-title":"Diabetes"},{"key":"2026102015013949200_B20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2337\/diabetes.54.4.1150","article-title":"Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program","volume":"54","author":"The Diabetes Prevention Program Research Group","year":"2005","journal-title":"Diabetes"},{"key":"2026102015013949200_B21","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"2026102015013949200_B22","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.2337\/db13-0265","article-title":"Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates","volume":"62","author":"DeFronzo","year":"2013","journal-title":"Diabetes"},{"key":"2026102015013949200_B23","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/dc24-0491","article-title":"Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial","volume":"47","author":"Kahn","year":"2024","journal-title":"Diabetes Care"},{"key":"2026102015013949200_B24","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102015013949200_B25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102015013949200_B26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/dci22-0046","article-title":"Youth-onset type 2 diabetes: the epidemiology of an awakening epidemic","volume":"46","author":"Perng","year":"2023","journal-title":"Diabetes Care"},{"key":"2026102015013949200_B27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"key":"2026102015013949200_B28","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1109333","article-title":"A clinical trial to maintain glycemic control in youth with type 2 diabetes","volume":"366","author":"TODAY Study Group","year":"2012","journal-title":"N Engl J Med"},{"key":"2026102015013949200_B29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2337\/dc13-1879","article-title":"Restoring Insulin Secretion (RISE): design of studies of \u03b2-cell preservation in prediabetes and early type 2 diabetes across the life span","volume":"37","author":"The RISE Consortium","year":"2014","journal-title":"Diabetes Care"},{"key":"2026102015013949200_B30","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.2337\/dc18-0244","article-title":"Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp","volume":"41","author":"The RISE Consortium","year":"2018","journal-title":"Diabetes Care"},{"key":"2026102015013949200_B31","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2337\/dc18-0243","article-title":"Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: II. Observations using the oral glucose tolerance test","volume":"41","author":"The RISE Consortium","year":"2018","journal-title":"Diabetes Care"},{"key":"2026102015013949200_B32","first-page":"1670","article-title":"Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on \u03b2-cell function: comparison of responses in youth and adults","volume":"68","author":"RISE Consortium Investigators","year":"2019","journal-title":"Diabetes"},{"key":"2026102015013949200_B33","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"},{"key":"2026102015013949200_B34","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2337\/dc21-0460","article-title":"Hyperglucagonemia does not explain the \u03b2-cell hyperresponsiveness and insulin resistance in dysglycemic youth compared with adults: lessons from the RISE Study","volume":"44","author":"Kahn","year":"2021","journal-title":"Diabetes Care"},{"key":"2026102015013949200_B35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s42255-023-00970-0","article-title":"Genetic architecture and biology of youth-onset type 2 diabetes","volume":"6","author":"Kwak","year":"2024","journal-title":"Nat Metab"},{"key":"2026102015013949200_B36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1463-1326.2008.00969.x","article-title":"Pancreatic beta-cell mass in European subjects with type 2 diabetes","volume":"10","author":"Rahier","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"2026102015013949200_B37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/cells2020266","article-title":"Linking metabolic abnormalities to apoptotic pathways in beta cells in type 2 diabetes","volume":"2","author":"Wali","year":"2013","journal-title":"Cells"},{"key":"2026102015013949200_B38","doi-asserted-by":"crossref","first-page":"703538","DOI":"10.1155\/2012\/703538","article-title":"Mitochondrial dysfunction and \u03b2-cell failure in type 2 diabetes mellitus","volume":"2012","author":"Ma","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"2026102015013949200_B39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","article-title":"Pancreatic \u03b2-cells in type 1 and type 2 diabetes mellitus: different pathways to failure","volume":"16","author":"Eizirik","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026102015013949200_B40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41574-021-00510-4","article-title":"Therapeutic opportunities for pancreatic \u03b2-cell ER stress in diabetes mellitus","volume":"17","author":"Yong","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026102015013949200_B41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1210\/me.2014-1367","article-title":"Minireview: autophagy in pancreatic \u03b2-cells and its implication in diabetes","volume":"29","author":"Watada","year":"2015","journal-title":"Mol Endocrinol"},{"key":"2026102015013949200_B42","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","article-title":"Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells","volume":"84","author":"Westermark","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102015013949200_B43","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102015013949200_B44","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1073\/pnas.86.15.5738","article-title":"Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone","volume":"86","author":"Nishi","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102015013949200_B45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/diab.39.5.634","article-title":"Evidence of cosecretion of islet amyloid polypeptide and insulin by \u03b2-cells","volume":"39","author":"Kahn","year":"1990","journal-title":"Diabetes"},{"key":"2026102015013949200_B46","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2337\/diabetes.47.4.640","article-title":"Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans","volume":"47","author":"Kahn","year":"1998","journal-title":"Diabetes"},{"key":"2026102015013949200_B47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102015013949200_B48","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","article-title":"Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Billings","year":"2025","journal-title":"Lancet"},{"key":"2026102015013949200_B49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00403322","article-title":"Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians","volume":"33","author":"Clark","year":"1990","journal-title":"Diabetologia"},{"key":"2026102015013949200_B50","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ajpath.2011.02.036","article-title":"\u03b2-cell loss and \u03b2-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition","volume":"178","author":"Jurgens","year":"2011","journal-title":"Am J Pathol"},{"key":"2026102015013949200_B51","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s00125-010-1671-6","article-title":"Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?","volume":"53","author":"Zraika","year":"2010","journal-title":"Diabetologia"},{"key":"2026102015013949200_B52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2337\/diabetes.48.3.491","article-title":"The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles","volume":"48","author":"Janson","year":"1999","journal-title":"Diabetes"},{"key":"2026102015013949200_B53","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1073\/pnas.93.8.3492","article-title":"Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide","volume":"93","author":"Verchere","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102015013949200_B54","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2337\/diabetes.47.5.743","article-title":"Islet amyloid-associated diabetes in obese A(vy)\/a mice expressing human islet amyloid polypeptide","volume":"47","author":"Soeller","year":"1998","journal-title":"Diabetes"},{"key":"2026102015013949200_B55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s001250051175","article-title":"Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model","volume":"42","author":"H\u00f6ppener","year":"1999","journal-title":"Diabetologia"},{"key":"2026102015013949200_B56","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2006.12.187","article-title":"Glucose- and time-dependence of islet amyloid formation in vitro","volume":"354","author":"Zraika","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2026102015013949200_B57","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00125-008-1255-x","article-title":"Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis","volume":"52","author":"Zraika","year":"2009","journal-title":"Diabetologia"},{"key":"2026102015013949200_B58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"2026102015013949200_B59","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.2337\/db13-0863","article-title":"Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1\u03b2 production and \u03b2-cell dysfunction","volume":"63","author":"Westwell-Roper","year":"2014","journal-title":"Diabetes"},{"key":"2026102015013949200_B60","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat Immunol"},{"key":"2026102015013949200_B61","first-page":"307","article-title":"The bimodal effect of interleukin 1 on rat pancreatic beta-cells--stimulation followed by inhibition--depends upon dose, duration of exposure, and ambient glucose concentration","volume":"119","author":"Spinas","year":"1988","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2026102015013949200_B62","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s00125-020-05232-2","article-title":"Low concentration IL-1\u03b2 promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro","volume":"63","author":"Templin","year":"2020","journal-title":"Diabetologia"},{"key":"2026102015013949200_B63","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00125-009-1329-4","article-title":"Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress","volume":"52","author":"Hull","year":"2009","journal-title":"Diabetologia"},{"key":"2026102015013949200_B64","doi-asserted-by":"crossref","first-page":"C1586","DOI":"10.1152\/ajpcell.00208.2007","article-title":"Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro","volume":"293","author":"Hull","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026102015013949200_B65","doi-asserted-by":"crossref","first-page":"18177","DOI":"10.1074\/jbc.M109.082032","article-title":"Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation","volume":"285","author":"Zraika","year":"2010","journal-title":"J Biol Chem"},{"key":"2026102015013949200_B66","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/en.2016-1410","article-title":"Inhibition of insulin-degrading enzyme does not increase islet amyloid deposition in vitro","volume":"157","author":"Hogan","year":"2016","journal-title":"Endocrinology"},{"key":"2026102015013949200_B67","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2337\/diabetes.54.7.2235","article-title":"Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide","volume":"54","author":"Hull","year":"2005","journal-title":"Diabetes"},{"key":"2026102015013949200_B68","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s00125-011-2143-3","article-title":"Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets","volume":"54","author":"Aston-Mourney","year":"2011","journal-title":"Diabetologia"},{"key":"2026102015013949200_B69","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets","volume":"144","author":"Farilla","year":"2003","journal-title":"Endocrinology"},{"key":"2026102015013949200_B70","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1038\/s41467-023-41986-0","article-title":"A human antibody against pathologic IAPP aggregates protects beta cells in type 2 diabetes models","volume":"14","author":"Wirth","year":"2023","journal-title":"Nat Commun"},{"key":"2026102015013949200_B71","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1073\/pnas.0401781101","article-title":"Pauling and Corey\u2019s alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease","volume":"101","author":"Armen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102015013949200_B72","doi-asserted-by":"crossref","first-page":"e4854","DOI":"10.1002\/pro.4854","article-title":"Human islet amyloid polypeptide-induced \u03b2-cell cytotoxicity is linked to formation of \u03b1-sheet structure","volume":"33","author":"Hsu","year":"2024","journal-title":"Protein Sci"},{"key":"2026102015013949200_B73","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00125-018-4695-y","article-title":"Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice","volume":"61","author":"Templin","year":"2018","journal-title":"Diabetologia"},{"key":"2026102015013949200_B74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1210\/jc.2009-0572","article-title":"Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes","volume":"95","author":"Zinman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026102015013949200_B75","doi-asserted-by":"crossref","first-page":"101877","DOI":"10.1016\/j.molmet.2024.101877","article-title":"RIPK3 promotes islet amyloid-induced \u03b2-cell loss and glucose intolerance in a humanized mouse model of type 2 diabetes","volume":"80","author":"Mukherjee","year":"2024","journal-title":"Mol Metab"},{"key":"2026102015013949200_B76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mce.2013.02.003","article-title":"Expression and roles of steroidogenic acute regulatory (StAR) protein in 'non-classical', extra-adrenal and extra-gonadal cells and tissues","volume":"371","author":"Anuka","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"2026102015013949200_B77","doi-asserted-by":"crossref","first-page":"bqaf027","DOI":"10.1210\/endocr\/bqaf027","article-title":"Increased steroidogenic acute regulatory protein contributes to cholesterol-induced \u03b2-cell dysfunction","volume":"166","author":"Akter","year":"2025","journal-title":"Endocrinology"},{"key":"2026102015013949200_B78","doi-asserted-by":"crossref","first-page":"130-OR","DOI":"10.2337\/db21-130-OR","article-title":"130-OR: statin exposure increases Star (steroidogenic acute regulatory protein) expression in islets: a novel mechanism for \u03b2-cell dysfunction and increased diabetes risk?","volume":"70","author":"Hogan","year":"2021","journal-title":"Diabetes"},{"key":"2026102015013949200_B79","doi-asserted-by":"crossref","first-page":"1239335","DOI":"10.3389\/fendo.2023.1239335","article-title":"Statins and risk of type 2 diabetes: mechanism and clinical implications","volume":"14","author":"Laakso","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026102015013949200_B80","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s00125-014-3304-y","article-title":"Islet amyloid formation is an important determinant for inducing islet inflammation in high-fat-fed human IAPP transgenic mice","volume":"57","author":"Meier","year":"2014","journal-title":"Diabetologia"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/75\/11\/1954\/898096\/dbi250024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/75\/11\/1954\/898096\/dbi250024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:01:53Z","timestamp":1792522913000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/11\/1954\/172735\/Revisiting-the-Cell-The-Key-to-the-Type-2-Diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":80,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,10,20]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi25-0024","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}